Published in final edited form as:

J Rheumatol. 2017 September ; 44(9): 1331–1340. doi:10.3899/jrheum.161214.

Patient reported outcomes as predictors of change in disease activity and disability in early rheumatoid arthritis: results from Yorkshire Early Arthritis Register

Sarah Twigg, MD^{1,2} [Clinical lecturer], Elizabeth MA Hensor, PhD^{1,2} [Biostatistician], YEAR Consortium³, Paul Emery, PhD^{1,2,¶} [Arthritis Research UK Professor of rheumatology], Alan Tennant, PhD^{1,4,¶} [Senior Advisor], and Ann W Morgan, PhD^{1,2,¶,*} [Professor of Molecular Rheumatology/ Hon. Consultant Rheumatologist]

¹Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), School of Medicine, University of Leeds, Leeds, LS9 7TF, United Kingdom (UK) ²National Institute for Health Research- Leeds Musculoskeletal Biomedical Research Unit, Chapel Allerton Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, UK ³Yorkshire Early Arthritis Register Consortium – see Appendix I for membership ⁴Swiss Paraplegic Research, Nottwil, Switzerland

Abstract

Objective—To assess patient reported variables as predictors of change in disease activity and disability in early rheumatoid arthritis (RA).

Methods—Cases were recruited to Yorkshire Early Arthritis Register (YEAR) between 1997 and 2009 (n=1415). Predictors of 28-joint Disease Activity Score (DAS28) and Health Assessment

Corresponding Author: Leeds Institute Rheumatic and Musculoskeletal Medicine, Wellcome Trust Brenner Building, St. James's University Hospital, Leeds, LS9 7TF, UK, a.w.morgan@leeds.ac.uk (AWM).

[¶]Each of these authors contributed equally to this work and should be considered joint senior authors

Footline: PROMs as predictors

YEAR consortium membership:

MANAGEMENT TEAM : Prof. Paul Emery^{1,2}, Prof. Philip Conaghan^{1,2}, Prof. Ann Morgan^{1,2}, Prof Anne-Maree Keenan¹ and Dr Elizabeth Hensor¹ MEDICAL STAFF: Dr Mark Quinn³, Dr Andrew Gough⁴, Dr Michael Green^{3,4}, Dr Richard Reece⁵, Dr Lesley Hordon⁶, Dr Philip Helliwell^{1,7}, Dr Richard Melsom⁷, Dr Sheelagh Doherty⁸, Dr Ade Adebajo⁹, Dr Andrew Harvey¹⁰, Dr Steve Jarrett¹⁰, Dr Gareth Huston¹, Dr Amanda Isdale³, Dr Mike Martin², Dr Zunaïd Karim¹⁰, Prof. Dennis McGonagle^{1,11}, Dr Colin Pease², Dr Sally Cox², Dr Victoria Bejarano¹, Dr Jackie Nam^{1,2}, Dr Edith Villeneuve^{1,2} and Dr Sarah Twigg^{1,2} NURSING STAFF: Claire Brown¹, Christine Thomas¹, David Pickles¹, Alison Hammond¹, Beverley Nevill^{4,3}, Alan Fairclough⁵, Caroline Nunns⁵, Anne Gill³, Julie Green³, Belinda Rhys-Evans², Barbara Padwell², Julie Madden¹¹, Lynda Taylor¹¹, Sally Smith², Heather King², Jill Firth⁷, Jayne Heard⁸ and Linda Sigsworth⁷ SUPPORT STAFF: Diane Corscadden¹, Karen Henshaw¹, Lubna-Haroon Rashid¹, Stephen G. Martin¹, Dr James I. Robinson¹, Dr Lukasz Kozera¹, Dr Agata Burska¹, Sarah Fahy¹ and Andrea Paterson¹

1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK

2. Leeds Teaching Hospitals NHS trust, UK

3. York District Hospital, York, UK

4. Harrogate District Hospital, Harrogate, UK

5. Huddersfield Royal Infirmary, Huddersfield, UK

6. Dewsbury District and General Hospital, Dewsbury, UK

7. St Luke's Hospital, Bradford, UK

8. Hull Royal Infirmary, Hull, UK

9. Barnsley District General Hospital, Barnsley, UK

10. Pinderfields hospital, Wakefield, UK

11. Calderdale Local Hospital, Halifax, UK

Questionnaire Disability Index (HAQ-DI) at baseline and change over 12 months were identified using multilevel models. Baseline predictors were: gender, age, symptom duration, autoantibody status, pain and fatigue visual analogue scores (VAS), duration of early morning stiffness (EMS), DAS28 and HAQ-DI.

Results—Rates of change were slower in women than men: DAS28 fell by 0.19 and 0.17, and HAQ-DI by 0.028 and 0.023 units per month in men and women, respectively. Baseline pain and EMS had small effects on rates of change, whereas fatigue VAS was only associated with DAS28 and HAQ-DI at baseline. In patients recruited up to 2002 DAS28 reduced more quickly in those with greater pain at baseline (by 0.01 units/month of DAS28 per centimetre pain VAS; $p=0.024$); in patients recruited after 2002 the effect for pain was stronger (by 0.01 units/month; $p=0.087$). DAS28 reduction was greater with longer EMS. In both cohorts fall in HAQ-DI ($p=0.006$) was greater in patients with longer EMS duration, but pain and fatigue were not significant predictors of change in HAQ-DI.

Conclusion—Patient reported fatigue, pain and stiffness at baseline are of limited value for the prediction of RA change in disease activity (DAS28) and activity limitation (HAQ-DI).

Keywords

Rheumatoid arthritis; cohort study; outcomes; pain

Introduction

The use of patient reported outcomes to assess treatment response in rheumatoid arthritis (RA) is well-established. The core set of outcomes recommended for assessment of RA treatment by the Outcome Measures in Rheumatology Clinical Trials (OMERACT) group includes patient reported variables, such as pain and fatigue^{1, 2}. Measurement of these subjective indicators of health status can aid clinical assessment³ and there is evidence that they can be useful to help predict RA remission. For example, a study involving 103 RA patients from Japan found an inverse association between remission and greater pain and fatigue at baseline after a 7 year follow-up⁴. Similarly, greater baseline pain was associated with reduced odds of remission at 6 and /or 12 months in the French early inflammatory arthritis 'ESPOIR' cohort⁵. Thus, patient reported measures may be rapid and cost-effective tools for the prediction of outcome in RA. However, before these variables can be useful in a clinical setting, further evidence to support their application is needed. The present study evaluated patient reported measures (fatigue, pain and early morning stiffness) alongside traditional predictors of outcome to investigate their value in predicting the rate of change in disease activity and disability an early RA cohort.

Methods

Subjects

Yorkshire Early Arthritis Register (YEAR) is an observational inception cohort whose subjects were aged over 18 with a consultant made diagnosis of recent onset RA. The present study used data from 1415 participants recruited to YEAR between 1997 and 2009 with inflammatory symptom durations of ≥ 24 months. Details of YEAR were published

previously 6. Briefly, data on RA patients were collated from 14 rheumatology outpatient centres across Yorkshire, United Kingdom. Participants were treated according to a regionally agreed protocol that recommended sequential escalation of treatment with disease modifying anti-rheumatic drugs (DMARDs). When data collection began in 1997, the first-line DMARD was sulphasalazine (SSA), but this changed to methotrexate (MTX), with a one-off dose of intramuscular methylprednisolone (120mg) given at baseline, when the data collection and treatment protocols were altered in 2002. Deviations from the treatment protocol were made at the discretion of the treating rheumatologist. For the present analysis, patient data were not included if the symptom duration exceeded 24 months, or was missing. All patients provided written consent for inclusion into the study and ethical approval was granted by the Northern and Yorkshire Research Ethics Committee (MREC /99/3/48).

Data Collection

Data were collected at baseline, 3, 6, 9 (after 2002) and 12 months by a clinician or research nurse. Details captured included gender, date of birth, date of symptom onset, swollen and tender joint counts from a score of 28 (SJC and TJC), and duration of early morning stiffness (EMS) in minutes. Participants completed self-assessment tools, which included visual analogue scores (VAS) to indicate their assessment of pain (0 to 100 millimetre [mm] scale, where 0=no pain, 100=pain as bad as it can be) and fatigue (0=no abnormal fatigue and 100=fatigue as bad as it can be). The disability index component of the health assessment questionnaire (HAQ) was completed at each visit and is referred to as the HAQ-DI from here onwards. The SJC and TJC of 28 joints and C-reactive protein (CRP) were used to calculate the three variable disease activity score⁷ (DAS28-CRP) for each visit. Laboratory analyses undertaken at individual recruitment centres included CRP at all visits and IgM rheumatoid factor (RF) at baseline. RF was measured using standard nephelometric assays and anti-citrullinated peptide antibodies (ACPA) were determined retrospectively on stored samples, using previously described methods⁸.

Data analysis

Baseline demographic and disease characteristics were summarized in terms of means and standard errors (continuous variables) and percentages (categorical variables). Multilevel models (random intercepts, fixed slopes) were constructed to evaluate baseline predictors of DAS28 and HAQ-DI measured at baseline, 6 and 12 months. These were 2-level models in which repeated measurements over time (level 1) were nested within patients (level 2). These models included an indicator for 'cohort' (before or after 2002, when the treatment protocol changed), and a variable indicating month, which was treated as a continuous covariate. Interactions were added between each predictor and cohort, to show whether associations with baseline DAS28 or HAQ-DI differed by cohort, and between each predictor and month, to show whether the predictor was associated with change in DAS28 over time. Additionally, 3-way interaction terms between each predictor, month and cohort were added to explore whether changes over time differed by cohort. The interaction terms were sequentially discarded in order of least significance until only significant terms (where $p < 0.1$) remained in the model; 2-way interactions were retained irrespective of significance if both variables were included in a significant 3-way interaction. Linear change was assumed over time. Pseudo-adjusted-R-squared was calculated as the adjusted-R-squared

between observed and predicted values of each outcome. R-squared estimates obtained in each imputed dataset were averaged after using Fisher's r to z transformation. We considered whether random slopes were more suitable than fixed slopes. Formally testing for random slopes using the standard likelihood ratio approach is not currently supported for multiply-imputed datasets in our chosen analysis package. We compared the coefficients between models that included fixed or random slopes for time and found them to be very similar, and the conclusions regarding which main effects and interactions were statistically significant remained unaffected, therefore we opted to retain the simpler model.

Continuous rather than dichotomous outcomes (e.g. remission or non-remission, HAQ above or below a threshold value) were used in order to retain statistical power. To this end, as HAQ-DI represents an ordinal scale⁹, this variable was transformed using Rasch analysis so that it could be analysed as an interval-scaled variable¹⁰. As well as traditionally reported predictors of RA outcome - including gender, antibody status and age - patient reported pain, fatigue and duration of early morning stiffness were also included as predictors in the models. Continuous variables were centred at the mean prior to analysis. EMS was not normally distributed and was therefore divided into 5 approximately equal-sized groups: <30, 30-59, 60-119, 120-179, and 180 minutes. Correlation between RF and ACPA status was 0.56 and considered low enough for both variables to be included in the models simultaneously.

Missing Data

Missing data were accounted for using multiple imputation (MI) by chained equations and 50 imputed datasets, the results from which were combined according to Rubin's rules¹¹. Predictive mean matching with 10 nearest neighbours was used to impute continuous variables; for RF and ACPA logistic regression was used. Fifty imputations were chosen for this analysis in order to achieve 95% relative efficiency of the MI estimates^{11–13}, given the amount of missing data (40% missing and 43% missing for the 6 and 12 month analyses, respectively). Auxiliary variables were selected from the dataset and included in the imputation models if they correlated with predictor or outcome variables (Pearson correlation 0.7), or predicted missingness (significant predictors in logistic regression analyses). The order of imputation (which included auxiliary variables) was: TJC28, SJC28, CRP at baseline, 3, 6, and 12 months, HAQ at baseline, 6 and 12 months, and baseline pain VAS, fatigue VAS, EMS, age, sex, symptom duration, RF and ACPA. Summary statistics of the imputed datasets were examined and compared to those of the complete dataset, in order to check that imputed values were reasonable.

All analyses were conducted using Stata 13. (*Stata Statistical Software: Release 14.1*. College Station, TX: StataCorp LP)

Results

Baseline characteristics and missing data

Numbers of cases recruited to YEAR and included in the final analysis are shown in Figure 1. From a total of 1415 cases, 690 were recruited between 1997 and 2002 and 725 were

recruited after 2002. Baseline characteristics and rates of missingness for variables included in the analysis are given in Table 1. YEAR may be considered consistent with other early RA cohorts with 66% of cases female, an average age of onset 58 years and 71% RF positive. These summary statistics were similar for cases recruited before and after 2002, however, mean baseline DAS28 was lower for cases recruited after 2002 (4.8, compared to 5.4) and similar differences were seen in baseline HAQ-DI (1.18 compared to 1.28). Baseline pain and fatigue VAS were also slightly higher in the earlier cohort, with mean pain VAS 6.3cm pre-2002 and 5.3cm post 2002; and fatigue VAS 4.8cm and 4.5cm, respectively. In 21% of cases, some variables were missing at baseline. Cases with no missing data were slightly older (58.6 vs. 57.7 years) and reported slightly more baseline fatigue, with higher DAS28 and HAQ-DI values.

Change in DAS28

Table 2 gives the results of the multilevel model of change in DAS28. Baseline DAS28 was higher in patients recruited prior to 2002, older patients and those with longer disease duration, greater pain, fatigue and longer duration of early morning stiffness. On average, DAS28 reduced by 0.19 units per month in males and the rate of reduction was 0.02 units/month slower in females. Reduction in DAS28 per month was slightly faster in older patients (by 0.01 units per decade of baseline age). All of the statistically significant effects of baseline variables on change in DAS28 were small. At 12 months the estimated differences between patients according to gender, age (age 80 compared to age 50), and cohort (for values of pain VAS ranging from 4 to 8cm) did not exceed 0.6 DAS28 units. Pseudo-adjusted-R-squared for the DAS28 model was 0.30 (95% CI 0.28 to 0.32).

The association of baseline pain and stiffness with change in DAS28 differed depending on whether patients were recruited before or after 2002 (overall test of significance for stiffness $p=0.022$ and pain, $p=0.087$). In both cohorts greater pain VAS at baseline was associated with a slightly greater fall in DAS28 per month; this trend was stronger for patients recruited after 2002 (Figures 2a & 2b). In the earlier cohort baseline EMS was not associated with rate of change in DAS28, but in the later cohort, longer duration of EMS was associated with greater reduction in DAS28 (Figures 2c & 2d).

Repeating the final model using only cases with complete data yielded similar results to those obtained through MI, although with lower power. The effect of symptom duration on change over time was reduced in the MI analysis compared to complete cases, whereas the interaction between baseline pain, cohort and change over time was more apparent in the MI analysis.

Change in HAQ-DI

Table 3 shows the results of the multilevel model of HAQ-DI. As shown in Figure 3, higher baseline DAS28 and longer EMS duration were associated with slightly greater reduction in HAQ-DI and the effect of pain varied with cohort. Baseline HAQ-DI was higher in females than males by 0.217 units in cases recruited after 2002 and 0.091 units in cases recruited pre-2002, but the rate of change in HAQ-DI by gender was consistent between cohorts: average reduction was 0.028 units/month in males and 0.023 in females. As Figure 3c

illustrates, reduction in HAQ-DI was between 0.006 and 0.012 units/month faster in patients with EMS ≥ 30 mins compared to <30 mins (combined test of significance for all EMS categories $p=0.023$), and was 0.004 units/month faster per unit of baseline DAS28. Baseline pain was not associated with reduction in HAQ-DI in patients recruited up to 2002 (0.001 HAQ units per cm), but there was a slightly stronger trend in the later cohort (0.003 HAQ units per cm). Pseudo-adjusted-R-squared for the HAQ model was 0.24 (95% CI 0.22, 0.26).

Discussion

This study examined predictors of change in DAS28 and HAQ-DI in early RA, including patient reported measures, pain, fatigue and EMS, alongside traditional predictors of prognosis: gender, age and antibody status. The rate of reduction in DAS28 was greater with increased age at baseline and slower in females than males. It was also faster in those with greater pain or EMS at baseline, especially for our patients recruited after 2002. However, effects attributable to statistically significant variables were small. The measurement error of DAS is 0.6, and therefore a reduction from baseline of twice this (>1.20) is considered a good response¹⁴. In comparison, the present analyses predicted a reduction in DAS28 of 0.05 units per month in cases recruited after 2002 with EMS duration of ≥ 180 compared to <30 minutes (approximately 0.3 units after 6 months and 0.6 units after 12 months). Furthermore, fall in DAS28 was only 0.02 units per month faster per centimetre of baseline pain VAS in the later cohort where the effect was strongest. The effects of predictor variables on fall in HAQ-DI were also small: the rate of change in HAQ-DI was 0.005 units per month slower in females than males, and 0.004 units per month faster per unit of baseline DAS28. For those who reported ≥ 180 compared to <30 minutes of baseline EMS, fall in HAQ-DI was 0.012 units greater per month. In the present analyses, fatigue did not significantly impact the rate of change in HAQ-DI and pain had only a limited impact, restricted to the later cohort. Pain, fatigue and EMS as predictors of change in disease activity and disability are therefore unlikely to have direct clinical applications.

These findings are consistent with previously reported associations of patient reported symptoms and other outcomes. Recent data from the ESPOIR cohort found only a moderate correlation of fatigue and pain VAS with simultaneous DAS28 measurement, amongst other patient reported outcomes¹⁵. Female gender is frequently identified as an independent predictor of adverse outcome in RA, including non-remission¹⁶ and lesser reduction in DAS28¹⁷ and the results from the present study were consistent with this. Although some studies have found an association between increasing age at baseline and non-remission, this effect is not consistent between studies¹⁶ and therefore, our findings of only slightly faster reduction in DAS28 with increasing age at baseline was not surprising. There have also been several reported associations of increased age at RA onset with less favourable HAQ-DI^{18–20}, and although we did not find an association between rate of change in HAQ-DI and age, baseline HAQ-DI was higher for older patients.

Whether the findings of this study can be applied in the context of modern RA management is influenced by contemporary treatment approaches. Current treat-to-target recommendations for RA management were published in 2010²¹, which was after recruitment to YEAR ended. However, our findings may still be applicable for certain

patients, for example those who cannot take full doses of MTX or other DMARDs due to comorbidities or intolerance. The effect of treat-to-target on change in DAS28 and HAQ is an area of further study for the authors of this paper.

We are not aware of any other studies that have explored the use of patient reported outcomes to predict change in DAS28 and HAQ-DI in RA. However, several studies have highlighted the contribution of non-inflammatory pain to overall disease activity scores. The pain index of DAS28 (DAS28-P), described by researchers from the Early Rheumatoid Arthritis Network (ERAN)²², is the proportion of overall DAS28 derived from its subjective components.

Improvement in pain measured using the Short Form 36 questionnaire after 1 year was less likely in patients with higher baseline DAS28-P²². Recently, in patients from a Danish cohort of RA patients completing the painDETECT questionnaire (which is designed to classify pain into low, medium or high likelihood of being non-nociceptive), those whose scores indicated non-nociceptive pain had greater overall DAS28 and DAS28-P, measured at the time of questionnaire completion²³. Therefore, any association of baseline pain with subsequent change in DAS28 (as seen predominantly in our post-2002 cohort) may reflect an association with the subjective DAS28 components, rather than inflammation alone.

EMS is a disabling symptom that fluctuates with RA disease activity²⁴, and helps to differentiate patients with RA from non-inflammatory arthralgia²⁵. In a prospective study that examined the effect of severity of EMS on early retirement, greater EMS at baseline was correlated with simultaneous measurements of DAS28, pain, and function, and those with severe stiffness at baseline were more likely to retire from employment within 3 years of follow up²⁶. Further findings from this study included an absence of association between EMS and radiographic progression, which was later supported by evidence from the Leiden Early Arthritis Clinic and ESPOIR cohorts in which prolonged EMS (>60 minutes) was not associated with poor prognosis in terms of radiographic outcome after 3-7 years, or failure to achieve remission after 5-10 years' follow up²⁷. Although our study reported an association of greater EMS at baseline with greater rate of reduction in DAS28 in some patients in conflict with previous reports, the size of the effect was small (up to 0.06 units fall in DAS28 per month) and is unlikely to be clinically significant.

Data on fatigue and pain were captured in the form of VAS. Other methods of assessment are available to measure these variables, but the VAS was chosen because it was simple and quick for patients to complete alongside the other questionnaires that formed part of the study. A systematic review of scales to measure fatigue in RA identified 23 different scales, of which 6, including the VAS, had reasonable evidence of validation²⁸. This review found evidence that a VAS performs reasonably well in terms of construct validity and discrimination, but there was little evidence to demonstrate reliability and a lack of a standardised format. However, although the VAS has its limitations, no other measures are superior in terms of validation, and furthermore, the single item VAS likely performs as well as other, more detailed measures of fatigue²⁹. Therefore, we feel the use of VAS was justified.

A significant limitation of this study was the quantity of missing data: 40% and 43% cases had missing values for the 6 and 12 month analyses, respectively. Despite clear evidence that modern missing data management techniques such as MI are superior, traditional approaches, such as analysis restricted to cases with no missing data (complete case analysis and weighted complete case analysis) are still reported. Not only does this technique lead to a loss of statistical power when cases with missing data are dropped, complete case analysis is also more likely to give biased estimates^{30, 31}. The MI models created for the present analyses were carefully constructed, which involved scrutiny of the dataset to identify auxiliary variables, inclusion of all variables in the analysis model within the imputation model, and comparison of results to a complete case model. Due to the large quantity of missing data, we cannot rule out bias in the results of the analyses due to missingness; however, simulation studies have demonstrated that MI is superior to complete case analysis, even when the quantity of missing data is large³². Nevertheless, potential bias due to missing data should be considered when interpreting our findings. For example, we found no relationship between RF and ACPA positivity and adverse outcome, in contrast to previous reports that indicated an inverse association between autoantibodies and future remission^{33, 34}. Evidence for the relationship between autoantibodies and HAQ has been mixed, with some evidence of an association between autoantibodies and worse disability^{20, 35}, and some evidence to indicate there is no relationship between antibodies and HAQ^{36, 37}. The quantity of missing data was large for ACPA (39% of cases), so this is a potential source of bias.

An additional strength is the use of DAS28 and HAQ-DI as continuous, rather than categorical or dichotomous (remission/ non-remission) outcomes, thus improving statistical power. Although this study considered three separate patient reported measures as predictors of outcome, it was not possible to assess the predictive value of several other similar variables. These include the RAPID3³⁸ and SF36³⁹, which were not collected in YEAR, and the VAS of global health status, which was collected in YEAR, but was not included in the statistical models because it was strongly correlated with pain VAS. The present study was also limited to examining the predictive value of patient reported outcomes collected at the baseline visit. It is possible that trends in the change of these variables would be more useful as predictors of outcome and therefore could be an area of interest for future study.

In summary, this study showed that patient reported outcomes at baseline, such as pain, fatigue and stiffness are not useful for the prediction of rate of change in disease activity and disability.

Acknowledgements

The work of ST is supported by a NIHR clinical lectureship and this project is supported by the National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit. YEAR was in part supported by a programme grant from Arthritis Research UK and the NIHR-Leeds Musculoskeletal Biomedical Research Unit. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

Funding support:

Arthritis Research Campaign (now Arthritis Research UK), National Institute for Health Research.

References

1. Boers M, Tugwell P, Felson DT, van Riel PL, Kirwan JR, Edmonds JP, et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. *J Rheumatol Suppl.* 1994; 41:86–9. [PubMed: 7799394]
2. Kirwan JR, Minnock P, Adebajo A, Bresnihan B, Choy E, de Wit M, et al. Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. *J Rheumatol.* 2007; 34:1174–7. [PubMed: 17477482]
3. Pincus T, Gibson KA, Berthelot JM. Is a patient questionnaire without a joint examination as undesirable as a joint examination without a patient questionnaire? *J Rheumatol.* 2014; 41:619–21. [PubMed: 24692600]
4. Kojima M, Kojima T, Suzuki S, Takahashi N, Funahashi K, Asai S, et al. Patient-reported outcomes as assessment tools and predictors of long-term prognosis: a 7-year follow-up study of patients with rheumatoid arthritis. *Int J Rheum Dis [Internet].* 2015; Available from: doi: 10.1111/1756-185X.12789
5. Castrejón I, Dougados M, Combe B, Fautrel B, Guillemin F, Pincus T. Prediction of Remission in a French Early Arthritis Cohort by RAPID3 and other Core Data Set Measures, but Not by the Absence of Rheumatoid Factor, Anticitrullinated Protein Antibodies, or Radiographic Erosions. *J Rheumatol.* 2016; 43:1285–91. [PubMed: 27084913]
6. Conaghan PG, Hensor EM, Keenan AM, Morgan AW, Emery P. Persistently moderate DAS-28 is not benign: loss of function occurs in early RA despite step-up DMARD therapy. *Rheumatology.* 2010; 49:1894–9. [PubMed: 20542894]
7. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. *Arthritis Rheum.* 1995; 38:44–8. [PubMed: 7818570]
8. Morgan AW, Thomson W, Martin SG, Yorkshire Early Arthritis Register C, Carter AM, Consortium UKRAG. et al. Reevaluation of the interaction between HLA-DRB1 shared epitope alleles, PTPN22, and smoking in determining susceptibility to autoantibody-positive and autoantibody-negative rheumatoid arthritis in a large UK Caucasian population. *Arthritis Rheum.* 2009; 60:2565–76. [PubMed: 19714585]
9. Tennant A, Hillman M, Fear J, Pickering A, Chamberlain MA. Are we making the most of the Stanford Health Assessment Questionnaire? *Br J Rheumatol.* 1996; 35:574–8. [PubMed: 8670580]
10. Tennant A, Conaghan PG. The Rasch measurement model in rheumatology: what is it and why use it? When should it be applied, and what should one look for in a Rasch paper? *Arthritis Rheum.* 2007; 57:1358–62. [PubMed: 18050173]
11. Rubin, DI. Multiple imputation for non response in surveys. New York: Wiley; 1987.
12. Schafer JL. Multiple imputation: a primer. *Stat Methods Med Res.* 1999; 8:3–15. [PubMed: 10347857]
13. Newgard CD, Haukoos JS. Advanced statistics: missing data in clinical research--part 2: multiple imputation. *Acad Emerg Med.* 2007; 14:669–78. [PubMed: 17595237]
14. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. *Arthritis Rheum.* 1996; 39:34–40. [PubMed: 8546736]
15. Che H, Combe B, Morel J, Cantagrel A, Gossec L, Lukas C. Performance of patient-reported outcomes in the assessment of rheumatoid arthritis disease activity: the experience of the ESPOIR cohort. *Clin Exp Rheumatol.* 2016; 34:646–54. [PubMed: 27384748]
16. Katchamart W, Johnson S, Lin H-JL, Phumethum V, Salliot C, Bombardier C. Predictors for remission in rheumatoid arthritis patients: A systematic review. *Arthritis Care Res.* 2010; 62:1128–43.

17. Arnold MB, Bykerk VP, Boire G, Haraoui BP, Hitchon C, Thorne C, et al. Are there differences between young- and older-onset early inflammatory arthritis and do these impact outcomes? An analysis from the CATCH cohort. *Rheumatology*. 2014; 53:1075–86. [PubMed: 24501240]
18. Camacho EM, Verstappen SM, Lunt M, Bunn DK, Symmons DP. Influence of age and sex on functional outcome over time in a cohort of patients with recent-onset inflammatory polyarthritis: results from the Norfolk Arthritis Register. *Arthritis Care Res*. 2011; 63:1745–52.
19. Combe B, Rinccheval N, Benessiano J, Berenbaum F, Cantagrel A, Daures JP, et al. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort. *J Rheumatol*. 2013; 40:1650–7. [PubMed: 23950185]
20. Graell E, Vazquez I, Larrosa M, Rodriguez-Cros JR, Hernandez MV, Gratacos J, et al. Disability measured by the modified health assessment questionnaire in early rheumatoid arthritis: prognostic factors after two years of follow-up. *Clin Exp Rheumatol*. 2009; 27:284–91. [PubMed: 19473570]
21. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. *Ann Rheum Dis*. 2010; 69:631–7. [PubMed: 20215140]
22. McWilliams DF, Zhang W, Mansell JS, Kiely PDW, Young A, Walsh DA. Predictors of Change in Bodily Pain in Early Rheumatoid Arthritis: An Inception Cohort Study. *Arthritis Care & Research*. 2012; 64:1505–13. [PubMed: 22556121]
23. Christensen AW, Rifbjerg-Madsen S, Christensen R, Dreyer L, Tillingsøe H, Seven S, et al. Non-nociceptive pain in rheumatoid arthritis is frequent and affects disease activity estimation: cross-sectional data from the FRAME study. *Scandinavian Journal of Rheumatology*. 2016; 45:461–69. [PubMed: 26987470]
24. Orbai A-M, Halls S, Hewlett S, Bartlett SJ, Leong AL, Bingham CO, et al. More than Just Minutes of Stiffness in the Morning: Report from the OMERACT Rheumatoid Arthritis Flare Group Stiffness Breakout Sessions. *The Journal of Rheumatology*. 2015; 42:2182–84. [PubMed: 25729035]
25. van Steenberg HW, Aletaha D, Beaart-van de Voorde LJJ, Brouwer E, Codreanu C, Combe B, et al. EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. *Annals of the Rheumatic Diseases*. 2016
26. Westhoff G, Buttgereit F, Gromnica-Ihle E, Zink A. Morning stiffness and its influence on early retirement in patients with recent onset rheumatoid arthritis. *Rheumatology*. 2008; 47:980–84. [PubMed: 18413345]
27. van Nies JA, Alves C, Radix-Bloemen AL, Gaujoux-Viala C, Huizinga TW, Hazes JM, et al. Reappraisal of the diagnostic and prognostic value of morning stiffness in arthralgia and early arthritis: results from the Groningen EARC, Leiden EARC, ESPOIR, Leiden EAC and REACH. *Arthritis Research & Therapy*. 2015; 17:108. [PubMed: 25904188]
28. Hewlett S, Hehir M, Kirwan JR. Measuring fatigue in rheumatoid arthritis: A systematic review of scales in use. *Arthritis Care & Research*. 2007; 57:429–39. [PubMed: 17394228]
29. Wolfe F. Fatigue assessments in rheumatoid arthritis: comparative performance of visual analog scales and longer fatigue questionnaires in 7760 patients. *The Journal of Rheumatology*. 2004; 31:1896–902. [PubMed: 15468350]
30. Greenland S, Finkle WD. A critical look at methods for handling missing covariates in epidemiologic regression analyses. *Am J Epidemiol*. 1995; 142:1255–64. [PubMed: 7503045]
31. Knol MJ, Janssen KJ, Donders AR, Egberts AC, Heerdink ER, Grobbee DE, et al. Unpredictable bias when using the missing indicator method or complete case analysis for missing confounder values: an empirical example. *J Clin Epidemiol*. 2010; 63:728–36. [PubMed: 20346625]
32. Janssen KJ, Vergouwe Y, Donders AR, Harrell FE Jr, Chen Q, Grobbee DE, et al. Dealing with missing predictor values when applying clinical prediction models. *Clin Chem*. 2009; 55:994–1001. [PubMed: 19282357]
33. van der Woude D, Young A, Jayakumar K, Mertens BJ, Toes RE, van der Heijde D, et al. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. *Arthritis Rheum*. 2009; 60:2262–71. [PubMed: 19644846]

34. van der Woude D, Visser K, Klarenbeek NB, Roday HK, Peeters AJ, Kerstens PJ, et al. Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies. *Rheumatology (Oxford)*. 2012; 51:1120–8. [PubMed: 22337939]
35. Quinn MA, Gough AK, Green MJ, Devlin J, Hensor EM, Greenstein A, et al. Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. *Rheumatology (Oxford)*. 2006; 45:478–80. [PubMed: 16287917]
36. Dirven L, Visser K, Klarenbeek NB, Ewals JA, Han KH, Peeters AJ, et al. Towards personalized treatment: predictors of short-term HAQ response in recent-onset active rheumatoid arthritis are different from predictors of rapid radiological progression. *Scand J Rheumatol*. 2012; 41:15–9. [PubMed: 22103436]
37. Norton S, Sacker A, Dixey J, Done J, Williams P, Young A, et al. Trajectories of functional limitation in early rheumatoid arthritis and their association with mortality. *Rheumatology (Oxford)*. 2013; 52:2016–24. [PubMed: 23934221]
38. Pincus T, Bergman MJ, Yazici Y, Hines P, Raghupathi K, Maclean R. An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures. *Rheumatology*. 2008; 47:345–49. [PubMed: 18238788]
39. Jenkinson C, Coulter A, Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. *Bmj*. 1993; 306:1437–40. [PubMed: 8518639]

Figure 1. Cases recruited and included in analysis

Figure 2. Estimated DAS28 at varying values of a) pain VAS in patients recruited up to 2002 b) pain VAS in patients recruited after 2002 c) EMS in patients recruited up to 2002 d) EMS in patients recruited after 2002

Figure 3. Estimated HAQ-DI at varying values of a) pain VAS in patients recruited up to 2002 b) pain VAS in patients recruited after 2002 c) EMS in both cohorts d) DAS28 in both cohorts

Table 1
Cohort characteristics and rates of missing data from 1415 cases in Yorkshire Early Arthritis Register

Categorical data:	Number of cases (%)	Number of cases with missing data (%)
Female	932 (66)	(0) (0)
RF positive	952 (71)	82 (6)
ACPA positive	553 (64)	553 (39)
Duration EMS		45 (3)
0-29 minutes	271 (20)	
30-59 minutes	172 (13)	
60-119 minutes	346 (25)	
120-179 minutes	236 (17)	
180 minutes	345 (25)	
Continuous data:	Mean (SD)	Number of cases with missing data (%)
Age in years	57.7 (14.2)	0 (0)
Symptom duration in months ^a	7.1 (4.3)	0 (0)
Pain VAS in cm	6.1 (2.6)	90 (6)
Fatigue VAS in cm	5.3 (2.9)	291 (21)
DAS28-CRP (baseline)	5.01 (1.33)	157 (11)
HAQ-DI (baseline)	1.22 (0.57)	72 (5)
DAS28-CRP (6 months)	3.64 (1.57)	449 (32)
HAQ-DI (6 months)	0.97 (0.64)	302 (21)
DAS28-CRP (12 months)	3.22 (1.48)	413 (29)
HAQ-DI (12 months)	0.89 (0.63)	344 (24)

^aCases with missing values for symptom duration were excluded in order to focus the analysis on outcome in early RA.

ACPA, Anti-citrullinated peptide antibodies; DAS28-CRP; 3-variable disease activity score based on counts of 28 joints and C-reactive protein; EMS, early morning stiffness; HAQ-DI, disability index of Health Assessment Questionnaire; RF, rheumatoid factor; VAS, visual analogue score.

Table 2
Results of multilevel regression models of change in DAS28

	Imputed data (n=1415)			Complete case (n=614)		
	Coefficient	SE	P	Coefficient	SE	P
Predictors of baseline DAS28						
Cohort (post-2002 vs. pre-2002)	-0.65	0.18	<0.001	-0.45	0.26	0.090
Female	-0.06	0.08	0.435	-0.07	0.11	0.510
Age	0.09	0.03	<0.001	0.09	0.04	0.026
Symptom duration	-0.02	0.01	0.019	-0.03	0.01	0.033
RF positive	-0.04	0.10	0.718	-0.13	0.14	0.342
ACPA positive	0.03	0.12	0.808	0.15	0.13	0.271
Pain VAS (cm) (pre-2002)	0.14	0.02	<0.001	0.13	0.03	<0.001
Fatigue VAS (cm)	0.05	0.02	0.001	0.06	0.02	0.004
EMS duration (pre-2002):						
30-59	0.44	0.17	0.010	0.63	0.27	0.020
60-119	0.53	0.15	<0.001	0.44	0.22	0.048
120-179	0.72	0.18	<0.001	0.57	0.28	0.042
180	0.60	0.15	<0.001	0.53	0.25	0.035
Cohort differences in predictors of baseline DAS28 (post-2002 vs. pre-2002)						
Pain VAS (post-2002 vs. pre-2002)	0.02	0.03	0.555	-0.01	0.04	0.805
EMS duration (post-2002 vs. pre-2002):						
30-59	-0.50	0.27	0.061	-0.57	0.40	0.153
60-119	-0.24	0.23	0.289	-0.10	0.33	0.762
120-179	-0.49	0.25	0.055	-0.30	0.38	0.433
180	-0.20	0.23	0.380	0.01	0.35	0.981
Change in DAS28 per month*	-0.19	0.02	<0.001	-0.20	0.03	<0.001
Predictors of change in DAS28 (difference in change per month)						
Cohort (post-2002 vs. pre-2002)	0.03	0.02	0.103	0.03	0.03	0.303
Female	0.02	0.01	0.016	0.04	0.01	0.005
Age	-0.01	0.00	0.001	-0.01	0.00	0.041
Symptom duration	0.00	0.00	0.116	0.00	0.00	0.031
RF positive	0.01	0.01	0.364	0.02	0.02	0.177
ACPA positive	0.02	0.01	0.106	0.02	0.02	0.247
Pain VAS (cm) (pre-2002)	-0.01	0.00	0.024	-0.01	0.00	0.040
Fatigue VAS (cm)	0.00	0.00	0.224	0.00	0.00	0.479
EMS duration (pre-2002)						
30-59	0.02	0.02	0.489	-0.01	0.03	0.711
60-119	-0.02	0.02	0.395	-0.02	0.03	0.415
120-179	0.00	0.02	0.992	-0.02	0.03	0.536

	Imputed data (n=1415)			Complete case (n=614)		
	Coefficient	SE	P	Coefficient	SE	P
180	0.00	0.02	0.978	-0.01	0.03	0.651
Cohort differences in predictors of change in DAS28						
Pain VAS (cm) (post-2002 vs. pre-2002)	-0.01	0.00	0.087	0.00	0.00	0.808
EMS duration (post-2002 vs. pre-2002):						
30-59	-0.06	0.03	0.054	-0.04	0.04	0.348
60-119	0.00	0.02	0.926	0.03	0.04	0.428
120-179	-0.04	0.03	0.145	-0.03	0.04	0.431
180	-0.05	0.03	0.051	-0.06	0.04	0.097
Model constant	4.96	0.16	<0.001	4.95	0.24	<0.001

* (in seronegative males with EMS<30 and mean age, symptom duration, pain and fatigue VAS recruited pre-2002.)

Age was entered into the model as (age in years)/10

For EMS, the referent category was <30 minutes

ACPA, anti-citrullinated peptide antibodies; cm, centimetres; DAS28-CRP, 3-variable disease activity score from counts of 28 joints and C-reactive protein; EMS, early morning stiffness duration in minutes; p, probability (statistical significance); RF, rheumatoid factor; SE, standard error; VAS, visual analogue score.

Table 3
Results of multilevel regression models of change in HAQ-DI

	Imputed data (n=1416)			Complete case (n=579)		
	Coefficient	SE	P	Coefficient	SE	P
Predictors of baseline HAQ-DI						
Cohort: (post-2002 vs. pre-2002)	-0.120	0.048	0.012	-0.039	0.076	0.608
Female (pre-2002)	0.091	0.041	0.027	0.068	0.061	0.266
Age	0.028	0.011	0.009	0.026	0.018	0.136
Symptom duration (pre-2002)	0.006	0.005	0.205	0.012	0.007	0.106
RF positive	0.008	0.041	0.850	0.013	0.061	0.836
ACPA positive	-0.014	0.045	0.748	0.004	0.057	0.942
Pain VAS (cm) (pre-2002)	0.034	0.009	<0.001	0.042	0.013	0.001
Fatigue VAS	0.029	0.006	<0.001	0.029	0.009	0.002
DAS28	0.135	0.013	<0.001	0.123	0.020	<0.001
EMS duration						
30-59	0.006	0.053	0.912	0.025	0.085	0.765
60-119	0.019	0.046	0.681	-0.003	0.070	0.971
120-179	0.096	0.051	0.061	0.076	0.080	0.344
180	0.134	0.047	0.005	0.139	0.077	0.072
Cohort differences in predictors of baseline HAQ-DI (post-2002 vs. pre-2002)						
Female	0.126	0.054	0.021	0.121	0.086	0.160
Symptom duration	-0.012	0.006	0.063	-0.015	0.010	0.131
Pain VAS	0.008	0.011	0.461	-0.008	0.017	0.661
Change in HAQ-DI per month*	-0.028	0.005	<0.001	-0.031	0.007	<0.001
Predictors of change in HAQ-DI (difference in change per month)						
Cohort: (post-2002 vs. pre-2002)	-0.004	0.003	0.133	-0.003	0.004	0.477
Female	0.005	0.003	0.089	0.009	0.004	0.033
Age	0.001	0.001	0.368	0.002	0.002	0.294
Symptom duration	0.000	0.000	0.300	0.001	0.000	0.199
RF positive	0.001	0.004	0.877	-0.005	0.005	0.392
ACPA positive	0.006	0.004	0.189	0.012	0.005	0.014
Pain VAS (cm) (pre-2002)	-0.001	0.001	0.215	0.000	0.001	0.737
Fatigue VAS (cm)	0.000	0.001	0.887	0.000	0.001	0.947
DAS28CRP	-0.004	0.001	<0.001	-0.005	0.002	0.002
EMS duration						
30-59	-0.006	0.005	0.181	-0.012	0.007	0.108
60-119	-0.002	0.004	0.684	0.002	0.006	0.749
120-179	-0.002	0.005	0.603	0.004	0.007	0.589
180	-0.012	0.004	0.006	-0.014	0.007	0.037

	Imputed data (n=1416)			Complete case (n=579)		
	Coefficient	SE	P	Coefficient	SE	P
Cohort differences in predictors of change in HAQ-DI						
Pain VAS						
(post-2002 vs. pre-2002)	-0.002	0.001	0.053	-0.002	0.001	0.250
Model Constant	1.105	0.055	<0.001	1.096	0.085	<0.001

* in seronegative males with EMS<30 and mean age, symptom duration, DAS28, pain and fatigue VAS recruited pre-2002

Age was entered into the model as (age in years)/10

For EMS, the referent category was <30 minutes

ACPA, anti-citrullinated peptide antibodies; cm, centimetres; DAS28-CRP, 3-variable disease activity score from counts of 28 joints and C-reactive protein; EMS, early morning stiffness duration in minutes; HAQ-DI, disability index of the health assessment questionnaire; p, probability (statistical significance); RF, rheumatoid factor; SE, standard error; VAS, visual analogue score.